ATRA241220C1000
- 0.05
- 0.000.00%
Atara Biotherapeutics Newsroom
Atara Biotherapeutics Reports Q3 2024 Financial Progress
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Raises Target Price to $21
Canaccord Genuity Maintains Buy on Atara Biotherapeutics, Raises Price Target to $21
Atara Biotherapeutics GAAP EPS of -$2.93 Beats by $17.16, Revenue of $40.19M Beats by $5.02M
Atara Biotherapeutics Advances With Strategic Partnerships
Atara Biotherapeutics: Cash Runway Into 2027 Enables Key Pipeline Readouts >ATRA
Atara Biotherapeutics: First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected 1Q of 2025 >ATRA
Atara Biotherapeutics: Tab-cel U.S. BLA On-Track With PDUFA Target Action Date of Jan 15, 2025 >ATRA
Atara Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q3 Revenue $40.2M
Atara Biotherapeutics 3Q Loss $21.9M >ATRA
Express News | Atara Biotherapeutics Q3 Revenue USD 40.19 Million Vs. IBES Estimate USD 35.2 Million
Here Are the Major Earnings After the Close Today
Insights Into Atara Biotherapeutics's Upcoming Earnings
Earnings Preview: ATRA to Report Financial Results Post-market on November 12
$Atara Biotherapeutics(ATRA.US)$ is scheduled to release its financial results post-market on November 12 ET. Earnings PreviewAnalysts estimate $Atara Biotherapeutics(ATRA.US)$ to post revenue of USD3
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Express News | Atara Biotherapeutics- Appointed Eric Hyllengren to Serve as Chief Operating Officer, in Addition to Role as CFO
Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)